Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.40B | $6.18B | $6.64B | $5.53B | $4.97B | $6.34B | $6.83B | $6.08B | $5.78B | $5.81B |
| Revenue growth | — | 14.5% | 7.4% | -16.8% | -10.1% | 27.7% | 7.7% | -11.0% | -4.9% | 0.4% |
| Gross profit | $1.10B | $1.75B | $1.97B | $1.06B | $1.07B | $1.38B | $1.62B | $1.30B | $1.14B | $902M |
| Gross margin | 20.4% | 28.2% | 29.7% | 19.2% | 21.5% | 21.8% | 23.7% | 21.4% | 19.8% | 15.5% |
| Net income | $7.00M | $746M | $995M | -$52.0M | $219M | $608M | $578M | -$253M | $69.0M | -$386M |
| Net margin | 0.1% | 12.1% | 15.0% | -0.9% | 4.4% | 9.6% | 8.5% | -4.2% | 1.2% | -6.6% |
| EPS (diluted) | $0.04 | $3.91 | $5.45 | -$0.32 | $1.32 | $3.60 | $3.65 | -$1.70 | $0.46 | -$2.57 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $594M | $640M | $1.14B | $650M | $807M | $814M | $755M | $556M | -$633M | $264M |
| Capital expenditures | $338M | $411M | $498M | $481M | $267M | $277M | $307M | $370M | $360M | $213M |
| Free cash flow | $256M | $229M | $642M | $169M | $540M | $537M | $448M | $186M | -$993M | $51.0M |
| Share buybacks | $0.00 | $106M | $644M | $322M | $0.00 | $173M | $495M | $69.0M | — | — |
| Dividends paid | $22.0M | $22.0M | $148M | $164M | $164M | $164M | $154M | $149M | $148M | $78.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $902M | $1.56B | $1.20B | $943M | $1.10B | $1.45B | $1.10B | $1.20B | $713M | $670M |
| Total assets | $6.06B | $7.29B | $7.36B | $7.26B | $7.08B | $7.55B | $7.64B | $8.24B | $7.51B | $7.38B |
| Total liabilities | $5.96B | $6.43B | $6.34B | $6.56B | $6.27B | $6.47B | $6.53B | $7.52B | $6.94B | $6.81B |
| Long-term debt | $3.53B | $4.10B | $3.96B | $4.03B | $4.00B | $3.72B | $3.59B | $3.99B | $4.06B | $4.07B |
| Shareholders' equity | $100M | $860M | $1.01B | $689M | $813M | $1.08B | $1.11B | $721M | $571M | $566M |
| Retained earnings | -$114M | $579M | $1.47B | $1.25B | $1.30B | $1.75B | $2.17B | $1.78B | $1.69B | $1.64B |
| Shares (wtd avg diluted) | 183M | 191M | 183M | 165M | 166M | 169M | 158M | 149M | 150M | 150M |
Every figure is extracted from Chemours Co’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.